English name： Cyclosporin
3、Mechanism and clinical use:
Cyclosporin (also as Cyclosporin A) is a ring type polypeptide containing 11 amino acid residues. It is a very strong immunosuppressant. It can inhibit generation of cell-mediated reaction. At the cell level, it inhibits generation and release of lymphokine factor including interleukin 2 (T-cell growth factor (TCGF)). It can block the resting lymphocyte at cell cycle G0 or G1 phase, and inhibit antigen-triggered lymphokine factor release through activated T-cells. It is evidenced that Cyclosporin can specifically and reversibly act on lymphocyte, but not to influence function of hematopoietic and phagocytic cells. Substantial organ and bone marrow transplantations succeed by using Cyclosporin to prevent and treat rejection reaction and graft versus-host diseases. Besides, Cyclosporin has therapy effect on many known or possibly autoimmunity-caused diseases.
It is used in anti-rejection of organ grafting and selective autoimmunity diseases.
On June. 2020, Cyclosporin passed GMP certification .
On Dec .2020, API Cyclosporin was granted “written confirmation for active substance exported to EU”.
4、Packaging size specification
Inner package: single-layers polyethylene bag and aluminum foil bag.
Outer package: aluminum bottle (pharmaceutical use).
Packaging size: 10kg/bottle